Overview
- Fourth-quarter revenue came in at $11.46 billion versus roughly $11.8 billion expected, while adjusted EPS of $1.50 matched forecasts.
- Diagnostics sales fell 2.5% to $2.46 billion and Nutrition declined 8.9% to $1.94 billion, partly offset by 12.3% growth in Medical Devices to $5.68 billion with continuous glucose monitor sales of $2.0 billion up 15%.
- Abbott guided first-quarter adjusted EPS to $1.12–$1.18, below the roughly $1.20 consensus, and set 2026 targets for $5.55–$5.80 in adjusted EPS with 6.5%–7.5% organic sales growth.
- Shares dropped about 7% in Thursday trading, touching a new 52-week low following the revenue miss and cautious outlook.
- Management flagged new device approvals (FDA approval for the Volt PFA system and a CE Mark for the TactiFlex Duo catheter) plus the roughly $21 billion Exact Sciences deal, expected to close in the second quarter, as offsets to diagnostics pressures tied to COVID test declines, China procurement programs, and the Libre 3 safety alert.